Non-Small Cell Lung Cancer New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC Ulas D. Bayraktar, MD 2023-09-23
Uterine Cancer New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer Ulas D. Bayraktar, MD 2023-09-23
Follicular Lymphoma New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Multiple Myeloma New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma Ulas D. Bayraktar, MD 2023-09-23
Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Drug: Glofitamab for Large B Cell Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Renal Cell Carcinoma New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC Ulas D. Bayraktar, MD 2023-08-20
Colorectal Cancer New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2023-08-20
Diffuse Large B Cell Lymphoma New Drug: Glofitamab in Large B-Cell Lymphoma Ulas D. Bayraktar, MD 2023-08-20
